Ultragenyx Announces Incentive Grant in Nasdaq Listing

NOVATO, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on developing and commercializing novel therapies for rare and ultra-rare diseases, today announced a grant of 22,405 restricted share units of the Company’s common stock to six newly hired non-executive officers of the Company. The awards were approved by the Compensation Committee of the Company’s Board of Directors and were granted under the Ultragenyx Employment Inducement Plan, with a grant date of October 16, 2024, as incentive material for new employees joining Ultragenyx pursuant to Nasdaq Listing Rule 5635(c)(4).

The Restricted Stock Units vest over a period of four years, with 25% of the underlying shares vesting on each anniversary of the grant date, provided that the employee is in continuous employment with the Company as of such expiration date.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to providing patients with novel products to treat serious rare and ultra-rare genetic diseases. The Company has built a diverse portfolio of approved therapies and product candidates aimed at treating diseases with high unmet medical needs and clear biology for treatment, for which there are typically no approved therapies to treat the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is based on time- and cost-efficient drug development with the aim of providing safe and effective therapies to patients with the highest priority.

For more information about Ultragenyx, please visit the Company’s website at: www.ulbarenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370